Analyse du bon usage du rituximab

Circulaire DHOS-E2/DSS-1C n° 2006-30 du 19 janvier 2006 relative à la mise en œuvre du contrat de bon usage des médicaments et produits et prestations mentionné à l’article L. 162-22-7 du Code de la Sécurité sociale. Décret 2005-1023 du 24 août 2005 relatif au contrat de bon usage des médicaments et des produits et prestations mentionné à l’article L. 162-22-7 du Code de la Sécurité sociale. Journal officiel, 26 août 2005. Résumé des caractéristiques du produit. Mabthéra®, rituximab. Vidal, 2008. Société française d’hématologie (SFH). Recommandations concernant le bon usage du rituximab (Mabthéra®) en hématologie, 2006. Braendstrup, 2005, Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura, Am J Hematol, 78, 275, 10.1002/ajh.20276 Garcia-Chavez, 2007, Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis, Ann Hematol, 86, 871, 10.1007/s00277-007-0317-3 Narat, 2005, Rituximab in the treatment of refractory autoimmune cytopenias in adults, Haematologica, 90, 1273 Vigna-Perez, 2006, Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study, Arthritis Res Ther, 8, R83, 10.1186/ar1954 Franchini, 2007, Rituximab in the treatment of adult acquired hemophilia A: a systematic review, Crit Rev Oncol Hematol, 63, 47, 10.1016/j.critrevonc.2006.11.004 Eriksson, 2005, Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab, J Intern Med, 257, 540, 10.1111/j.1365-2796.2005.01494.x Choquet, 2006, Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study, Blood, 107, 3053, 10.1182/blood-2005-01-0377 Sansonno, 2003, Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20, Blood, 101, 3818, 10.1182/blood-2002-10-3162 Au, 2007, Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab, Br J Haematol, 137, 475, 10.1111/j.1365-2141.2007.06588.x Bader-Meunier, 2007, Rituximab therapy for childhood Evans syndrome, Haematologica, 92, 1691, 10.3324/haematol.11540 Mandreoli, 2004, Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia, Am J Kidney Dis, 44, 757, 10.1053/j.ajkd.2004.06.016 Guigonis, 2008, Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases, Pediatr Nephrol, 23, 1269, 10.1007/s00467-008-0814-1 Bagga, 2007, Rituximab in patients with the steroid-resistant nephrotic syndrome, N Engl J Med, 356, 2751, 10.1056/NEJMc063706 Becker, 2004, Rituximab as treatment for refractory kidney transplant rejection, Am J Transplant, 4, 996, 10.1111/j.1600-6143.2004.00454.x Alausa, 2005, Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab, Clin Transplant, 19, 137, 10.1111/j.1399-0012.2004.00292.x Lehnhardt, 2006, Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab, Am J Transplant, 6, 847, 10.1111/j.1600-6143.2006.01246.x Ruggenenti, 2003, Rituximab in idiopathic membranous nephropathy: a one-year prospective study, Am Soc Nephrol, 14, 1851, 10.1097/01.ASN.0000071511.35221.B3 Dudler, 2008, Rheumatoid arthritis and ankylosing spondylitis-rheumatologic highlights 2007, Rev Med Suisse, 4, 67 Rodríguez-Escalera, 2008, The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B, Rheumatology. (Oxford), 47, 1732, 10.1093/rheumatology/ken362 Seror, 2007, Tolerance and efficacy of rituximab and changes in serum B-cell biomarkers in patients with systemic complications of primary Sjögren's syndrome, Ann Rheum Dis, 66, 351, 10.1136/ard.2006.057919 Pijpe, 2005, Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study, Arthritis Rheum, 52, 2740, 10.1002/art.21260 Gottenberg, 2005, Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases, Ann Rheum Dis, 64, 913, 10.1136/ard.2004.029694 Voulgarelis, 2004, Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas, Rheumatology (Oxford), 43, 1050, 10.1093/rheumatology/keh248 Stübgen, 2008, B-cell-targeted therapy with rituximab and autoimmune neuromuscular disorders, J Neuroimmunol, 204, 1, 10.1016/j.jneuroim.2008.07.019 Kilidireas, 2006, Rituximab therapy in monoclonal IgM-related neuropathies, Leuk Lymphoma, 47, 859, 10.1080/14786410500441664 Cai, 2006, Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab, J Rheumatol, 33, 1197 Lamprecht, 2003, Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis, Ann Rheum Dis, 62, 1230, 10.1136/ard.2002.004929 Mok, 2007, Rituximab for refractory polymyositis: an open-label prospective study, J Rheumatol, 34, 1864 Gono, 2006, Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody, J Clin Neurosci, 13, 683, 10.1016/j.jocn.2005.09.008 Kuntzer, 2006, Treatment options for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), Rev Neurol (Paris), 162, 539, 10.1016/S0035-3787(06)75048-2 Briani, 2004, Rituximab-responsive CIDP, Eur J Neurol, 11, 788, 10.1111/j.1468-1331.2004.00911.x Cohen, 2008, Successful treatment of psoriatic arthritis with rituximab, Ann Rheum Dis, 67, 1647, 10.1136/ard.2007.085290 Baker, 2005, Treatment of Stiff person syndrome with rituximab, J Neurol Neurosurg Psychiatry, 76, 999, 10.1136/jnnp.2004.051144